Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.330 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Allogene Therapeutics, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Top 10 Highest Short Interest Stocks And 10 With Highest Cost To Borrow: Where Do Carvana, MicroStrategy, Fisker And AMC Rank? ↗

December 17, 2022

Investors often look for stocks with high short interest and a high cost to borrow, which could predict a potential short squeeze. New data shared by S3 Partners could signal which stocks investors are...

Via Benzinga

RH, HUYA, Bilibili And Some Other Big Stocks Moving Lower On Monday ↗

December 12, 2022

U.S. stocks traded higher, with the Dow Jones jumping more than 200 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗

December 08, 2022

-Clinical Data Due Next Week at ASH-

Via Benzinga

Expert Ratings for Allogene Therapeutics ↗

September 22, 2022

Within the last quarter, Allogene Therapeutics (NASDAQ:ALLO) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 12, 2022 ↗

December 12, 2022

Via Benzinga

Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform

November 29, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer

November 10, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences

November 09, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology

November 03, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase

November 02, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia

October 31, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022

October 26, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products

October 11, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

October 06, 2022

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Apple, Amazon, HP And Other Big Losers From Friday ↗

August 29, 2022

U.S. stocks closed sharply lower with the Dow Jones tumbling more than 1,000 points on Friday. Here is the list of some big stocks moving lower in the previous session.

Via Benzinga

Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday ↗

September 22, 2022

Gainers

Via Benzinga

What 5 Analyst Ratings Have To Say About Allogene Therapeutics ↗

August 10, 2022

Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Why Everbridge Jumped Over 17%; Here Are 90 Biggest Movers From Friday ↗

August 29, 2022

Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022 ↗

August 10, 2022

Via Benzinga

Allogene Therapeutics: Q2 Earnings Insights ↗

August 09, 2022

Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

July 27, 2022

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET

From Allogene Therapeutics, Inc.

Via GlobeNewswire

Beyond Meat, Canoo, Veru And More: 12 Short Squeeze Candidates To Watch ↗

July 20, 2022

One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze candidate. S3 Partners analyst Ihor Dusaniwsky has just released a...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022 ↗

July 15, 2022

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 15, 2022

Via Benzinga

89 Biggest Movers From Friday ↗

June 21, 2022

Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗

June 03, 2022

Via Benzinga

What 4 Analyst Ratings Have To Say About Allogene Therapeutics ↗

June 03, 2022

Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 17, 2022

Via Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data ↗

May 10, 2022

Via Benzinga

The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗

May 04, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.